{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:14:10Z","timestamp":1779236050603,"version":"3.51.4"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["159912"],"award-info":[{"award-number":["159912"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["159912"],"award-info":[{"award-number":["159912"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02663-y","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:03:16Z","timestamp":1779235396000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["GSK-3 regulates CD4-CD8 cooperation for super-armed CD8+ cytolytic T cells in immunotherapy against tumors"],"prefix":"10.1038","volume":"11","author":[{"given":"Bastien","family":"Mo\u00ebs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janna","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5693-8634","authenticated-orcid":false,"given":"Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil Ponnoor","family":"Anto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atena","family":"Nemati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhael","family":"Attias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Kazanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfeng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Castoun-Puckett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres Carlos","family":"Oroya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan Huong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Auryane Laure","family":"Cabald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thai Hien","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5295-9019","authenticated-orcid":false,"given":"Christopher E.","family":"Rudd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"2663_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/eji.200738044","volume":"38","author":"V Kalia","year":"2008","unstructured":"Kalia, V., Sarkar, S. & Ahmed, R. Fine-tuning CD4+ central memory T cell heterogeneity by strength of stimulation. Eur. J. Immunol. 38, 15\u201319 (2008).","journal-title":"Eur. J. Immunol."},{"key":"2663_CR2","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.4110\/in.2023.23.e41","volume":"23","author":"P Topchyan","year":"2023","unstructured":"Topchyan, P., Lin, S. & Cui, W. The role of CD4 T cell help in CD8 T cell differentiation and function during chronic infection and cancer. Immune Netw. 23, e41 (2023).","journal-title":"Immune Netw."},{"key":"2663_CR3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nri.2015.10","volume":"16","author":"BJ Laidlaw","year":"2016","unstructured":"Laidlaw, B. J., Craft, J. E. & Kaech, S. M. The multifaceted role of CD4(+) T cells in CD8(+) T cell memory. Nat. Rev. Immunol. 16, 102\u2013111 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"2663_CR4","doi-asserted-by":"publisher","first-page":"21182","DOI":"10.1073\/pnas.1118450109","volume":"108","author":"RD Aubert","year":"2011","unstructured":"Aubert, R. D. et al. Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection. Proc. Natl. Acad. Sci. USA 108, 21182\u201321187 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2663_CR5","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1128\/jvi.68.7.4700-4704.1994","volume":"68","author":"M Battegay","year":"1994","unstructured":"Battegay, M. et al. Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice. J. Virol. 68, 4700\u20134704 (1994).","journal-title":"J. Virol."},{"key":"2663_CR6","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","volume":"18","author":"J Borst","year":"2018","unstructured":"Borst, J., Ahrends, T., Babala, N., Melief, C. J. M. & Kastenmuller, W. CD4(+) T cell help in cancer immunology and immunotherapy. Nat. Rev. Immunol. 18, 635\u2013647 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"2663_CR7","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1084\/jem.188.12.2205","volume":"188","author":"AJ Zajac","year":"1998","unstructured":"Zajac, A. J. et al. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188, 2205\u20132213 (1998).","journal-title":"J. Exp. Med."},{"key":"2663_CR8","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.cell.2020.05.017","volume":"181","author":"DY Oh","year":"2020","unstructured":"Oh, D. Y. et al. Intratumoral CD4(+) T cells mediate anti-tumor cytotoxicity in human bladder cancer. Cell 181, 1612\u20131625 (2020).","journal-title":"Cell"},{"key":"2663_CR9","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41581-023-00733-w","volume":"19","author":"N Mikami","year":"2023","unstructured":"Mikami, N. & Sakaguchi, S. Regulatory T cells in autoimmune kidney diseases and transplantation. Nat. Rev. Nephrol. 19, 544\u2013557 (2023).","journal-title":"Nat. Rev. Nephrol."},{"key":"2663_CR10","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","volume":"41","author":"C Tay","year":"2023","unstructured":"Tay, C., Tanaka, A. & Sakaguchi, S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer Cell 41, 450\u2013465 (2023).","journal-title":"Cancer Cell"},{"key":"2663_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nri1027","volume":"3","author":"KJ Wood","year":"2003","unstructured":"Wood, K. J. & Sakaguchi, S. Regulatory T cells in transplantation tolerance. Nat. Rev. Immunol. 3, 199\u2013210 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"2663_CR12","doi-asserted-by":"crossref","unstructured":"McLane, L. M., Abdel-Hakeem, M. S. & Wherry, E. J. CD8 T cell exhaustion during chronic viral infection and cancer. Annu. Rev. Immunol. 37, 457\u2013495 (2019).","DOI":"10.1146\/annurev-immunol-041015-055318"},{"key":"2663_CR13","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.immuni.2019.11.002","volume":"51","author":"WH Hudson","year":"2019","unstructured":"Hudson, W. H. et al. Proliferating transitory T cells with an effector-like transcriptional signature emerge from PD-1(+) stem-like CD8(+) T cells during chronic infection. Immunity 51, 1043\u20131058 (2019).","journal-title":"Immunity"},{"key":"2663_CR14","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.immuni.2019.09.013","volume":"51","author":"Z Chen","year":"2019","unstructured":"Chen, Z. et al. TCF-1-centered transcriptional network drives an effector versus exhausted CD8 T cell-fate decision. Immunity 51, 840\u2013855 e845 (2019).","journal-title":"Immunity"},{"key":"2663_CR15","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112049","volume":"34","author":"SH Baumeister","year":"2016","unstructured":"Baumeister, S. H., Freeman, G. J., Dranoff, G. & Sharpe, A. H. Coinhibitory pathways in immunotherapy for cancer. Annu Rev. Immunol. 34, 539\u2013573 (2016).","journal-title":"Annu Rev. Immunol."},{"key":"2663_CR16","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/j.celrep.2016.10.032","volume":"17","author":"WW Lin","year":"2016","unstructured":"Lin, W. W. et al. CD8(+) T lymphocyte self-renewal during effector cell determination. Cell Rep. 17, 1773\u20131782 (2016).","journal-title":"Cell Rep."},{"key":"2663_CR17","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.immuni.2020.09.005","volume":"53","author":"D Pais Ferreira","year":"2020","unstructured":"Pais Ferreira, D. et al. Central memory CD8(+) T cells derive from stem-like Tcf7(hi) effector cells in the absence of cytotoxic differentiation. Immunity 53, 985\u20131000 (2020).","journal-title":"Immunity"},{"key":"2663_CR18","doi-asserted-by":"publisher","first-page":"911","DOI":"10.4049\/jimmunol.1700595","volume":"199","author":"JA Gullicksrud","year":"2017","unstructured":"Gullicksrud, J. A. et al. Differential requirements for Tcf1 long isoforms in CD8(+) and CD4(+) T cell responses to acute viral infection. J. Immunol. 199, 911\u2013919 (2017).","journal-title":"J. Immunol."},{"key":"2663_CR19","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1016\/j.celrep.2015.10.072","volume":"13","author":"WH Lin","year":"2015","unstructured":"Lin, W. H. et al. Asymmetric PI3K signaling driving developmental and regenerative cell fate bifurcation. Cell Rep. 13, 2203\u20132218 (2015).","journal-title":"Cell Rep."},{"key":"2663_CR20","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","volume":"11","author":"P Sharma","year":"2021","unstructured":"Sharma, P. et al. The next decade of immune checkpoint therapy. Cancer Discov. 11, 838\u2013857 (2021).","journal-title":"Cancer Discov."},{"key":"2663_CR21","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41577-023-00867-9","volume":"23","author":"K Chamoto","year":"2023","unstructured":"Chamoto, K., Yaguchi, T., Tajima, M. & Honjo, T. Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1. Nat. Rev. Immunol. 23, 682\u2013695 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"2663_CR22","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1158\/1078-0432.CCR-19-0402","volume":"25","author":"A Sharma","year":"2019","unstructured":"Sharma, A. et al. Anti-CTLA-4 immunotherapy does not deplete FOXP3(+) regulatory T cells (Tregs) in human cancers-response. Clin. Cancer Res. 25, 3469\u20133470 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2663_CR23","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734\u20131736 (1996).","journal-title":"Science"},{"key":"2663_CR24","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1158\/1078-0432.CCR-13-0143","volume":"19","author":"PA Ott","year":"2013","unstructured":"Ott, P. A., Hodi, F. S. & Robert, C. CTLA-4 and PD-1\/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin. Cancer Res. 19, 5300\u20135309 (2013).","journal-title":"Clin. Cancer Res."},{"key":"2663_CR25","doi-asserted-by":"publisher","first-page":"114907","DOI":"10.1016\/j.celrep.2024.114907","volume":"43","author":"E Ben Saad","year":"2024","unstructured":"Ben Saad, E., Oroya, A., Anto, N. P., Bachais, M. & Rudd, C. E. PD-1 endocytosis unleashes the cytolytic potential of checkpoint blockade in tumor immunity. Cell Rep. 43, 114907 (2024).","journal-title":"Cell Rep."},{"key":"2663_CR26","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui, I. et al. Intratumoral TCF1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50, 195\u2013211 (2019).","journal-title":"Immunity"},{"key":"2663_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01062-w","volume":"8","author":"M Sade-Feldman","year":"2017","unstructured":"Sade-Feldman, M. et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat. Commun. 8, 1136 (2017).","journal-title":"Nat. Commun."},{"key":"2663_CR28","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller, B. C. et al. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326\u2013336 (2019).","journal-title":"Nat. Immunol."},{"key":"2663_CR29","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nri819","volume":"2","author":"M Barry","year":"2002","unstructured":"Barry, M. & Bleackley, R. C. Cytotoxic T lymphocytes: all roads lead to death. Nat. Rev. Immunol. 2, 401\u2013409 (2002).","journal-title":"Nat. Rev. Immunol."},{"key":"2663_CR30","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/cdd.2009.206","volume":"17","author":"SP Cullen","year":"2010","unstructured":"Cullen, S. P., Brunet, M. & Martin, S. J. Granzymes in cancer and immunity. Cell Death Differ. 17, 616\u2013623 (2010).","journal-title":"Cell Death Differ."},{"key":"2663_CR31","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.4049\/jimmunol.2300334","volume":"212","author":"ZLZ Hay","year":"2024","unstructured":"Hay, Z. L. Z. et al. Granzyme F: exhaustion marker and modulator of chimeric antigen receptor T cell-mediated cytotoxicity. J. Immunol. 212, 1381\u20131391 (2024).","journal-title":"J. Immunol."},{"key":"2663_CR32","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1182\/blood-2002-08-2485","volume":"101","author":"H Johnson","year":"2003","unstructured":"Johnson, H., Scorrano, L., Korsmeyer, S. J. & Ley, T. J. Cell death induced by granzyme C. Blood 101, 3093\u20133101 (2003).","journal-title":"Blood"},{"key":"2663_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.626095","volume":"9","author":"CE Rudd","year":"2021","unstructured":"Rudd, C. E. How the discovery of the CD4\/CD8-p56(LCK) complexes changed immunology and immunotherapy. Front. Cell Dev. Biol. 9, 626095 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"2663_CR34","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1146\/annurev.immunol.20.092601.111357","volume":"20","author":"LE Samelson","year":"2002","unstructured":"Samelson, L. E. Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins. Annu Rev. Immunol. 20, 371\u2013394 (2002).","journal-title":"Annu Rev. Immunol."},{"key":"2663_CR35","doi-asserted-by":"crossref","unstructured":"Cantrell, D. Signaling in lymphocyte activation. Cold Spring Harb. Perspect. Biol. 7, a018788 (2015).","DOI":"10.1101\/cshperspect.a018788"},{"key":"2663_CR36","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0092-8674(00)80953-8","volume":"96","author":"CE Rudd","year":"1999","unstructured":"Rudd, C. E. Adaptors and molecular scaffolds in immune cell signaling. Cell 96, 5\u20138 (1999).","journal-title":"Cell"},{"key":"2663_CR37","doi-asserted-by":"crossref","unstructured":"Courtney, A. H. et al. CD45 functions as a signaling gatekeeper in T cells. Sci. Signal 12 (2019).","DOI":"10.1126\/scisignal.aaw8151"},{"key":"2663_CR38","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1073\/pnas.86.9.3277","volume":"86","author":"EK Barber","year":"1989","unstructured":"Barber, E. K., Dasgupta, J. D., Schlossman, S. F., Trevillyan, J. M. & Rudd, C. E. The CD4 and CD8 antigens are coupled to a protein-tyrosine kinase (p56lck) that phosphorylates the CD3 complex. Proc. Natl. Acad. Sci. USA 86, 3277\u20133281 (1989).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2663_CR39","doi-asserted-by":"crossref","unstructured":"Wei, Q. et al. LCK bound to coreceptor is less active than free LCK. Proc. Natl. Acad. Sci. USA 117, 15809\u201315817 (2020).","DOI":"10.1073\/pnas.1913334117"},{"key":"2663_CR40","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/0092-8674(92)90598-7","volume":"71","author":"AC Chan","year":"1992","unstructured":"Chan, A. C., Iwashima, M., Turck, C. W. & Weiss, A. ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell 71, 649\u2013662 (1992).","journal-title":"Cell"},{"key":"2663_CR41","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nature12229","volume":"499","author":"S Sharma","year":"2013","unstructured":"Sharma, S. et al. An siRNA screen for NFAT activation identifies septins as coordinators of store-operated Ca2+ entry. Nature 499, 238\u2013242 (2013).","journal-title":"Nature"},{"key":"2663_CR42","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.immuni.2016.01.018","volume":"44","author":"A Taylor","year":"2016","unstructured":"Taylor, A. et al. Glycogen synthase kinase 3 inactivation drives T-bet-mediated downregulation of co-receptor PD-1 to enhance CD8(+) cytolytic T cell responses. Immunity 44, 274\u2013286 (2016).","journal-title":"Immunity"},{"key":"2663_CR43","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1002\/j.1460-2075.1990.tb07419.x","volume":"9","author":"JR Woodgett","year":"1990","unstructured":"Woodgett, J. R. Molecular cloning and expression of glycogen synthase kinase-3\/factor A. EMBO J. 9, 2431\u20132438 (1990).","journal-title":"EMBO J."},{"key":"2663_CR44","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1242\/jcs.00384","volume":"116","author":"BW Doble","year":"2003","unstructured":"Doble, B. W. & Woodgett, J. R. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 116, 1175\u20131186 (2003).","journal-title":"J. Cell Sci."},{"key":"2663_CR45","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/j.1476-5381.2008.00085.x","volume":"156","author":"GV Rayasam","year":"2009","unstructured":"Rayasam, G. V., Tulasi, V. K., Sodhi, R., Davis, J. A. & Ray, A. Glycogen synthase kinase 3: more than a namesake. Br. J. Pharm. 156, 885\u2013898 (2009).","journal-title":"Br. J. Pharm."},{"key":"2663_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/bj3590001","volume":"359","author":"S Frame","year":"2001","unstructured":"Frame, S. & Cohen, P. GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 359, 1\u201316 (2001).","journal-title":"Biochem. J."},{"key":"2663_CR47","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/j.1460-2075.1993.tb05715.x","volume":"12","author":"K Hughes","year":"1993","unstructured":"Hughes, K., Nikolakaki, E., Plyte, S. E., Totty, N. F. & Woodgett, J. R. Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. Embo J. 12, 803\u2013808 (1993).","journal-title":"Embo J."},{"key":"2663_CR48","doi-asserted-by":"publisher","unstructured":"Eldar-Finkelman, H. & Martinez, A. GSK-3 inhibitors: preclinical and focus on CNS. Front. Mol. Neurosci. https:\/\/doi.org\/10.3389\/fnmol.2011.00032 (2011).","DOI":"10.3389\/fnmol.2011.00032"},{"key":"2663_CR49","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1084\/jem.192.1.99","volume":"192","author":"T Ohteki","year":"2000","unstructured":"Ohteki, T. et al. Negative regulation of T cell proliferation and interleukin 2 production by the serine threonine kinase GSK-3. J. Exp. Med. 192, 99\u2013104 (2000).","journal-title":"J. Exp. Med."},{"key":"2663_CR50","doi-asserted-by":"publisher","first-page":"1322670","DOI":"10.3389\/fimmu.2024.1322670","volume":"15","author":"B Zhang","year":"2024","unstructured":"Zhang, B., Feng, H., Lin, H. & Li, R. Somatostatin-SSTR3-GSK3 modulates human T-cell responses by inhibiting OXPHOS. Front. Immunol. 15, 1322670 (2024).","journal-title":"Front. Immunol."},{"key":"2663_CR51","doi-asserted-by":"publisher","first-page":"5664","DOI":"10.1158\/0008-5472.CAN-17-0799","volume":"77","author":"F Cichocki","year":"2017","unstructured":"Cichocki, F. et al. GSK3 inhibition drives maturation of NK cells and enhances their antitumor activity. Cancer Res. 77, 5664\u20135675 (2017).","journal-title":"Cancer Res."},{"key":"2663_CR52","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/j.1432-1033.1980.tb06059.x","volume":"107","author":"N Embi","year":"1980","unstructured":"Embi, N., Rylatt, D. B. & Cohen, P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur. J. Biochem. FEBS 107, 519\u2013527 (1980).","journal-title":"Eur. J. Biochem. FEBS"},{"key":"2663_CR53","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.pharmthera.2014.11.016","volume":"148","author":"E Beurel","year":"2015","unstructured":"Beurel, E., Grieco, S. F. & Jope, R. S. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharm. Ther. 148, 114\u2013131 (2015).","journal-title":"Pharm. Ther."},{"key":"2663_CR54","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41590-022-01194-2","volume":"23","author":"F Gounari","year":"2022","unstructured":"Gounari, F. & Khazaie, K. TCF-1: a maverick in T cell development and function. Nat. Immunol. 23, 671\u2013678 (2022).","journal-title":"Nat. Immunol."},{"key":"2663_CR55","first-page":"101457","volume":"34","author":"P Zhao","year":"2023","unstructured":"Zhao, P., Sun, L. & Zhao, C. TCF1\/LEF1 triggers WNT-dependent chemokine\/cytokine-induced inflammation and cadherin pathways to drive T-ALL cell migration. Biochem. Biophys. Rep. 34, 101457 (2023).","journal-title":"Biochem. Biophys. Rep."},{"key":"2663_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-020-04971-0","volume":"13","author":"A Taylor","year":"2020","unstructured":"Taylor, A. & Rudd, C. E. Glycogen synthase kinase 3 (GSK-3) controls T-cell motility and interactions with antigen presenting cells. BMC Res. Notes 13, 163 (2020).","journal-title":"BMC Res. Notes"},{"key":"2663_CR57","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/j.celrep.2020.01.076","volume":"30","author":"CE Rudd","year":"2020","unstructured":"Rudd, C. E., Chanthong, K. & Taylor, A. Small molecule inhibition of GSK-3 specifically inhibits the transcription of inhibitory co-receptor LAG-3 for enhanced anti-tumor immunity. Cell Rep. 30, 2075\u20132082 (2020).","journal-title":"Cell Rep."},{"key":"2663_CR58","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1158\/0008-5472.CAN-17-0491","volume":"78","author":"A Taylor","year":"2018","unstructured":"Taylor, A., Rothstein, D. & Rudd, C. E. Small-molecule inhibition of PD-1 transcription Is an effective alternative to antibody blockade in cancer therapy. Cancer Res. 78, 706\u2013717 (2018).","journal-title":"Cancer Res."},{"key":"2663_CR59","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.immuni.2017.04.003","volume":"46","author":"J Krueger","year":"2017","unstructured":"Krueger, J. & Rudd, C. E. Two strings in one bow: PD-1 negatively regulates via co-receptor CD28 on T cells. Immunity 46, 529\u2013531 (2017).","journal-title":"Immunity"},{"key":"2663_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102555","volume":"24","author":"L Steele","year":"2021","unstructured":"Steele, L. et al. Non-redundant activity of GSK-3alpha and GSK-3beta in T cell-mediated tumor rejection. iScience 24, 102555 (2021).","journal-title":"iScience"},{"key":"2663_CR61","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.3389\/fimmu.2017.01653","volume":"8","author":"A Taylor","year":"2017","unstructured":"Taylor, A. & Rudd, C. E. Glycogen synthase kinase 3 inactivation compensates for the lack of CD28 in the priming of CD8(+) cytotoxic T-cells: implications for anti-PD-1 immunotherapy. Front. Immunol. 8, 1653 (2017).","journal-title":"Front. Immunol."},{"key":"2663_CR62","doi-asserted-by":"crossref","unstructured":"Huntington, K. E. et al. GSK-3 inhibitor Elraglusib enhances tumor-infiltrating immune cell activation in tumor biopsies and synergizes with anti-PD-L1 in a murine model of colorectal cancer. Int. J. Mol. Sci. 24, 10870 (2023).","DOI":"10.3390\/ijms241310870"},{"key":"2663_CR63","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13045-022-01352-x","volume":"15","author":"G Shaw","year":"2022","unstructured":"Shaw, G., Cavalcante, L., Giles, F. J. & Taylor, A. Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8(+) T cell cytolytic killing of melanoma cells. J. Hematol. Oncol. 15, 134 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"2663_CR64","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/eji.1830220317","volume":"22","author":"NS Van Oers","year":"1992","unstructured":"Van Oers, N. S. et al. Disruption of CD8-dependent negative and positive selection of thymocytes is correlated with a decreased association between CD8 and the protein tyrosine kinase, p56lck. Eur. J. Immunol. 22, 735\u2013743 (1992).","journal-title":"Eur. J. Immunol."},{"key":"2663_CR65","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nature04444","volume":"439","author":"DL Barber","year":"2006","unstructured":"Barber, D. L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682\u2013687 (2006).","journal-title":"Nature"},{"key":"2663_CR66","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.immuni.2018.03.015","volume":"48","author":"D Herndler-Brandstetter","year":"2018","unstructured":"Herndler-Brandstetter, D. et al. KLRG1(+) effector CD8(+) T cells lose KLRG1, differentiate into all memory T cell lineages, and convey enhanced protective immunity. Immunity 48, 716\u2013729 (2018).","journal-title":"Immunity"},{"key":"2663_CR67","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adg0539","volume":"8","author":"AL Gill","year":"2023","unstructured":"Gill, A. L. et al. PD-1 blockade increases the self-renewal of stem-like CD8 T cells to compensate for their accelerated differentiation into effectors. Sci. Immunol. 8, eadg0539 (2023).","journal-title":"Sci. Immunol."},{"key":"2663_CR68","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nature19330","volume":"537","author":"SJ Im","year":"2016","unstructured":"Im, S. J. et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537, 417\u2013421 (2016).","journal-title":"Nature"},{"key":"2663_CR69","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/liv.14814","volume":"41","author":"HD Kim","year":"2021","unstructured":"Kim, H. D. et al. Implication of CD69(+) CD103(+) tissue-resident-like CD8(+) T cells as a potential immunotherapeutic target for cholangiocarcinoma. Liver Int. 41, 764\u2013776 (2021).","journal-title":"Liver Int."},{"key":"2663_CR70","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry, E. J. T cell exhaustion. Nat. Immunol. 12, 492\u2013499 (2011).","journal-title":"Nat. Immunol."},{"key":"2663_CR71","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.immuni.2023.12.006","volume":"57","author":"K Abadie","year":"2024","unstructured":"Abadie, K. et al. Reversible, tunable epigenetic silencing of TCF1 generates flexibility in the T cell memory decision. Immunity 57, 271\u2013286 (2024).","journal-title":"Immunity"},{"key":"2663_CR72","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1126\/science.abb2683","volume":"371","author":"K Xu","year":"2021","unstructured":"Xu, K. et al. Glycolysis fuels phosphoinositide 3-kinase signaling to bolster T cell immunity. Science 371, 405\u2013410 (2021).","journal-title":"Science"},{"key":"2663_CR73","doi-asserted-by":"publisher","first-page":"16310","DOI":"10.1002\/cam4.6247","volume":"12","author":"M Wu","year":"2023","unstructured":"Wu, M. et al. Glucose metabolism and function of CD4(+) tregs are regulated by the TLR8\/mTOR signal in an environment of SKOV3 cell growth. Cancer Med. 12, 16310\u201316322 (2023).","journal-title":"Cancer Med."},{"key":"2663_CR74","doi-asserted-by":"crossref","unstructured":"Sicheng F. et al. Immunometabolism regulates TCR recycling and iNKT cell functions. Sci. Signal 12, eaau1778 (2019).","DOI":"10.1126\/scisignal.aau1788"},{"key":"2663_CR75","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3109\/08830185.2015.1082178","volume":"35","author":"CS Palmer","year":"2016","unstructured":"Palmer, C. S. et al. Regulators of glucose metabolism in CD4(+) and CD8(+) T cells. Int. Rev. Immunol. 35, 477\u2013488 (2016).","journal-title":"Int. Rev. Immunol."},{"key":"2663_CR76","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S1074-7613(02)00323-0","volume":"16","author":"KA Frauwirth","year":"2002","unstructured":"Frauwirth, K. A. et al. The CD28 signaling pathway regulates glucose metabolism. Immunity 16, 769\u2013777 (2002).","journal-title":"Immunity"},{"key":"2663_CR77","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.cmet.2014.05.004","volume":"20","author":"AN Macintyre","year":"2014","unstructured":"Macintyre, A. N. et al. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab. 20, 61\u201372 (2014).","journal-title":"Cell Metab."},{"key":"2663_CR78","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/jcb.20950","volume":"99","author":"KR Gantt","year":"2006","unstructured":"Gantt, K. R. et al. The regulation of glucose transporter (GLUT1) expression by the RNA binding protein HuR. J. Cell Biochem. 99, 565\u2013574 (2006).","journal-title":"J. Cell Biochem."},{"key":"2663_CR79","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.cmet.2020.11.007","volume":"32","author":"RJ Arg\u00fcello","year":"2020","unstructured":"Arg\u00fcello, R. J. et al. SCENITH: a flow cytometry-based method to functionally profile energy metabolism with single-cell resolution. Cell Metab. 32, 1063\u20131075 (2020).","journal-title":"Cell Metab."},{"key":"2663_CR80","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","volume":"133","author":"S Sakaguchi","year":"2008","unstructured":"Sakaguchi, S., Yamaguchi, T., Nomura, T. & Ono, M. Regulatory T cells and immune tolerance. Cell 133, 775\u2013787 (2008).","journal-title":"Cell"},{"key":"2663_CR81","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.imlet.2018.05.001","volume":"205","author":"D Allard","year":"2019","unstructured":"Allard, D., Chrobak, P., Allard, B., Messaoudi, N. & Stagg, J. Targeting the CD73-adenosine axis in immuno-oncology. Immunol. Lett. 205, 31\u201339 (2019).","journal-title":"Immunol. Lett."},{"key":"2663_CR82","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","volume":"170","author":"SC Wei","year":"2017","unstructured":"Wei, S. C. et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170, 1120\u20131133 (2017).","journal-title":"Cell"},{"key":"2663_CR83","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1111\/j.1742-4658.2011.08072.x","volume":"278","author":"J Gomez-Rodriguez","year":"2011","unstructured":"Gomez-Rodriguez, J., Kraus, Z. J. & Schwartzberg, P. L. Tec family kinases Itk and Rlk \/ Txk in T lymphocytes: cross-regulation of cytokine production and T-cell fates. FEBS J. 278, 1980\u20131989 (2011).","journal-title":"FEBS J."},{"key":"2663_CR84","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.immuni.2024.04.001","volume":"57","author":"A Das","year":"2024","unstructured":"Das, A. et al. Transcription factor Tox2 is required for metabolic adaptation and tissue residency of ILC3 in the gut. Immunity 57, 1019\u20131036 (2024).","journal-title":"Immunity"},{"key":"2663_CR85","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev.immunol.20.100201.131730","volume":"20","author":"JH Russell","year":"2002","unstructured":"Russell, J. H. & Ley, T. J. Lymphocyte-mediated cytotoxicity. Annu. Rev. Immunol. 20, 323\u2013370 (2002).","journal-title":"Annu. Rev. Immunol."},{"key":"2663_CR86","doi-asserted-by":"publisher","first-page":"109","DOI":"10.5114\/ceji.2014.42135","volume":"39","author":"I Osinska","year":"2014","unstructured":"Osinska, I., Popko, K. & Demkow, U. Perforin: an important player in immune response. Cent. Eur. J. Immunol. 39, 109\u2013115 (2014).","journal-title":"Cent. Eur. J. Immunol."},{"key":"2663_CR87","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1073\/pnas.85.13.4814","volume":"85","author":"D Jenne","year":"1988","unstructured":"Jenne, D. et al. Identification and sequencing of cDNA clones encoding the granule-associated serine proteases granzymes D, E, and F of cytolytic T lymphocytes. Proc. Natl. Acad. Sci. USA 85, 4814\u20134818 (1988).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2663_CR88","doi-asserted-by":"publisher","first-page":"1661755","DOI":"10.3389\/fimmu.2025.1661755","volume":"16","author":"C Xin","year":"2025","unstructured":"Xin, C., Liu, P., Zhan, Q. & Cao, W. Gzmk(+) CD8 T cells in inflammatory diseases. Front. Immunol. 16, 1661755 (2025).","journal-title":"Front. Immunol."},{"key":"2663_CR89","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-025-08713-9","volume":"641","author":"CA Donado","year":"2025","unstructured":"Donado, C. A. et al. Granzyme K activates the entire complement cascade. Nature 641, 211\u2013221 (2025).","journal-title":"Nature"},{"key":"2663_CR90","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1038\/cdd.2009.101","volume":"16","author":"L Shi","year":"2009","unstructured":"Shi, L., Wu, L., Wang, S. & Fan, Z. Granzyme F induces a novel death pathway characterized by Bid-independent cytochrome c release without caspase activation. Cell Death Differ. 16, 1694\u20131706 (2009).","journal-title":"Cell Death Differ."},{"key":"2663_CR91","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abi8642","volume":"7","author":"BG Nixon","year":"2022","unstructured":"Nixon, B. G. et al. Cytotoxic granzyme C-expressing ILC1s contribute to antitumor immunity and neonatal autoimmunity. Sci. Immunol. 7, eabi8642 (2022).","journal-title":"Sci. Immunol."},{"key":"2663_CR92","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1128\/JVI.02528-08","volume":"83","author":"A Harari","year":"2009","unstructured":"Harari, A., Bellutti Enders, F., Cellerai, C., Bart, P. A. & Pantaleo, G. Distinct profiles of cytotoxic granules in memory CD8 T cells correlate with function, differentiation stage, and antigen exposure. J. Virol. 83, 2862\u20132871 (2009).","journal-title":"J. Virol."},{"key":"2663_CR93","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.0105-2896.2010.00894.x","volume":"235","author":"FC Kurschus","year":"2010","unstructured":"Kurschus, F. C. & Jenne, D. E. Delivery and therapeutic potential of human granzyme B. Immunol. Rev. 235, 159\u2013171 (2010).","journal-title":"Immunol. Rev."},{"key":"2663_CR94","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.4049\/jimmunol.2001334","volume":"207","author":"SC Vick","year":"2021","unstructured":"Vick, S. C., Kolupaev, O. V., Perou, C. M. & Serody, J. S. Anti-PD-1 Checkpoint Therapy Can Promote the Function and Survival of Regulatory T Cells. J. Immunol. 207, 2598\u20132607 (2021).","journal-title":"J. Immunol."},{"key":"2663_CR95","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1073\/pnas.1822001116","volume":"116","author":"T Kamada","year":"2019","unstructured":"Kamada, T. et al. PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc. Natl. Acad. Sci. USA 116, 9999\u201310008 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2663_CR96","doi-asserted-by":"publisher","first-page":"6236","DOI":"10.1158\/1078-0432.CCR-18-1100","volume":"24","author":"DM Woods","year":"2018","unstructured":"Woods, D. M. et al. Decreased suppression and increased phosphorylated STAT3 in regulatory T cells are associated with benefit from adjuvant PD-1 blockade in resected metastatic melanoma. Clin. Cancer Res. 24, 6236\u20136247 (2018).","journal-title":"Clin. Cancer Res."},{"key":"2663_CR97","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40425-018-0493-9","volume":"7","author":"E Dodagatta-Marri","year":"2019","unstructured":"Dodagatta-Marri, E. et al. alpha-PD-1 therapy elevates Treg\/Th balance and increases tumor cell pSmad3 that are both targeted by alpha-TGFbeta antibody to promote durable rejection and immunity in squamous cell carcinomas. J. Immunother. Cancer 7, 62 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"2663_CR98","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.immuni.2016.07.021","volume":"45","author":"DT Utzschneider","year":"2016","unstructured":"Utzschneider, D. T. et al. T cell factor 1-expressing memory-like CD8(+) T cells sustain the immune response to chronic viral infections. Immunity 45, 415\u2013427 (2016).","journal-title":"Immunity"},{"key":"2663_CR99","doi-asserted-by":"publisher","first-page":"14113","DOI":"10.1073\/pnas.1903520116","volume":"116","author":"RR Jadhav","year":"2019","unstructured":"Jadhav, R. R. et al. Epigenetic signature of PD-1+ TCF1+ CD8 T cells that act as resource cells during chronic viral infection and respond to PD-1 blockade. Proc. Natl. Acad. Sci. USA 116, 14113\u201314118 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2663_CR100","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s42003-024-05922-2","volume":"7","author":"TH Tu","year":"2024","unstructured":"Tu, T. H. et al. Decreased progenitor TCF1 + T-cells correlate with COVID-19 disease severity. Commun. Biol. 7, 526 (2024).","journal-title":"Commun. Biol."},{"key":"2663_CR101","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.cell.2017.04.004","volume":"169","author":"MD Buck","year":"2017","unstructured":"Buck, M. D., Sowell, R. T., Kaech, S. M. & Pearce, E. L. Metabolic Instruction of Immunity. Cell 169, 570\u2013586 (2017).","journal-title":"Cell"},{"key":"2663_CR102","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.it.2014.12.004","volume":"36","author":"D O\u2019Sullivan","year":"2015","unstructured":"O\u2019Sullivan, D. & Pearce, E. L. Targeting T cell metabolism for therapy. Trends Immunol. 36, 71\u201380 (2015).","journal-title":"Trends Immunol."},{"key":"2663_CR103","doi-asserted-by":"publisher","first-page":"1242454","DOI":"10.1126\/science.1242454","volume":"342","author":"EL Pearce","year":"2013","unstructured":"Pearce, E. L., Poffenberger, M. C., Chang, C. H. & Jones, R. G. Fueling immunity: insights into metabolism and lymphocyte function. Science 342, 1242454 (2013).","journal-title":"Science"},{"key":"2663_CR104","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.immuni.2016.07.008","volume":"45","author":"B Bengsch","year":"2016","unstructured":"Bengsch, B. et al. Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8(+) T cell exhaustion. Immunity 45, 358\u2013373 (2016).","journal-title":"Immunity"},{"key":"2663_CR105","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.celrep.2016.06.078","volume":"16","author":"A Schurich","year":"2016","unstructured":"Schurich, A. et al. Distinct metabolic requirements of exhausted and functional virus-specific CD8 T cells in the same host. Cell Rep. 16, 1243\u20131252 (2016).","journal-title":"Cell Rep."},{"key":"2663_CR106","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1016\/j.bbadis.2017.09.018","volume":"1863","author":"WF Theeuwes","year":"2017","unstructured":"Theeuwes, W. F. et al. Inactivation of glycogen synthase kinase-3beta (GSK-3beta) enhances skeletal muscle oxidative metabolism. Biochim. Biophys. Acta Mol. Basis Dis. 1863, 3075\u20133086 (2017).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"2663_CR107","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abk3147","volume":"8","author":"ME Ivanova","year":"2022","unstructured":"Ivanova, M. E. et al. The pore conformation of lymphocyte perforin. Sci. Adv. 8, eabk3147 (2022).","journal-title":"Sci. Adv."},{"key":"2663_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116256","volume":"44","author":"M Kandasamy","year":"2025","unstructured":"Kandasamy, M. et al. Glycogen synthase kinase-3 is essential for T(reg) development and function. Cell Rep. 44, 116256 (2025).","journal-title":"Cell Rep."},{"key":"2663_CR109","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41514-021-00056-9","volume":"7","author":"Z Ye","year":"2021","unstructured":"Ye, Z. et al. The GSK3beta-beta-catenin-TCF1 pathway improves naive T cell activation in old adults by upregulating miR-181a. npj Aging Mech. Dis. 7, 4 (2021).","journal-title":"npj Aging Mech. Dis."},{"key":"2663_CR110","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/s41423-023-01075-0","volume":"20","author":"Y Fu","year":"2023","unstructured":"Fu, Y. et al. Glycogen synthase kinase 3 controls T-cell exhaustion by regulating NFAT activation. Cell Mol. Immunol. 20, 1127\u20131139 (2023).","journal-title":"Cell Mol. Immunol."},{"key":"2663_CR111","doi-asserted-by":"crossref","unstructured":"Moes, B. & Rudd, C. E. Comment on: glycogen synthase kinase 3 controls T-cell exhaustion by regulating NFAT activation. Cell Mol. Immunol. 20, 1127\u20131139 (2025).","DOI":"10.1038\/s41423-023-01075-0"},{"key":"2663_CR112","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.immuni.2007.08.014","volume":"27","author":"X Cao","year":"2007","unstructured":"Cao, X. et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 27, 635\u2013646 (2007).","journal-title":"Immunity"},{"key":"2663_CR113","doi-asserted-by":"publisher","first-page":"101295","DOI":"10.1016\/j.smim.2019.101295","volume":"42","author":"J Krueger","year":"2019","unstructured":"Krueger, J., Rudd, C. E. & Taylor, A. Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications. Semin Immunol. 42, 101295 (2019).","journal-title":"Semin Immunol."},{"key":"2663_CR114","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.canlet.2018.06.035","volume":"433","author":"S Sengupta","year":"2018","unstructured":"Sengupta, S., Katz, S. C., Sengupta, S. & Sampath, P. Glycogen synthase kinase 3 inhibition lowers PD-1 expression, promotes long-term survival and memory generation in antigen-specific CAR-T cells. Cancer Lett. 433, 131\u2013139 (2018).","journal-title":"Cancer Lett."},{"key":"2663_CR115","doi-asserted-by":"publisher","first-page":"11","DOI":"10.46439\/cancerbiology.5.058","volume":"5","author":"AR Crespo","year":"2024","unstructured":"Crespo, A. R., Luna, S. G., Moes, B., Rodriguez, A. & Rudd, C. E. The many faceted role of glycogen synthase kinase-3 (GSK-3) in T cells and cancer immunotherapy. J. Cancer Biol. 5, 11\u201316 (2024).","journal-title":"J. Cancer Biol."},{"key":"2663_CR116","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/cei.13290","volume":"197","author":"M Attias","year":"2019","unstructured":"Attias, M., Al-Aubodah, T. & Piccirillo, C. A. Mechanisms of human FoxP3(+) T(reg) cell development and function in health and disease. Clin. Exp. Immunol. 197, 36\u201351 (2019).","journal-title":"Clin. Exp. Immunol."},{"key":"2663_CR117","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1074-7613(00)80422-7","volume":"6","author":"M Raab","year":"1997","unstructured":"Raab, M., da Silva, A. J., Findell, P. R. & Rudd, C. E. Regulation of Vav-SLP-76 binding by ZAP-70 and its relevance to TCR zeta\/CD3 induction of interleukin-2. Immunity 6, 155\u2013164 (1997).","journal-title":"Immunity"},{"key":"2663_CR118","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.immuni.2015.05.018","volume":"42","author":"J Helft","year":"2015","unstructured":"Helft, J. et al. GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c(+)MHCII(+) macrophages and dendritic cells. Immunity 42, 1197\u20131211 (2015).","journal-title":"Immunity"},{"key":"2663_CR119","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders, S., Pyl, P. T. & Huber, W. HTSeq\u2014a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166\u2013169 (2015).","journal-title":"Bioinformatics"},{"key":"2663_CR120","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"2663_CR121","doi-asserted-by":"crossref","unstructured":"Wickham, H. GGplot2: elegant graphics for data analysis. https:\/\/ggplot2.tidyverse.org (Springer, 2016).","DOI":"10.1007\/978-3-319-24277-4_9"},{"key":"2663_CR122","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2663_CR123","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1021\/acs.jproteome.8b00702","volume":"18","author":"NT Doncheva","year":"2019","unstructured":"Doncheva, N. T., Morris, J. H., Gorodkin, J. & Jensen, L. J. Cytoscape StringApp: network analysis and visualization of proteomics data. J. Proteome Res. 18, 623\u2013632 (2019).","journal-title":"J. Proteome Res."},{"key":"2663_CR124","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner, M. et al. Gene ontology: tool for the unification of biology. the gene ontology consortium. Nat. Genet. 25, 25\u201329 (2000).","journal-title":"Nat. Genet."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02663-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02663-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02663-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:03:19Z","timestamp":1779235399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02663-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":124,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2663"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02663-y","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"8 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.E.R has received consulting fees from Freshfields Bruckhaus Deringer LLP (UK), Bristows LLP (UK), Proskauer Rose LLP (US) for patent consultancy work and is the founder of ImmunAb Res Inc (Canada) with patents relating to immunotherapies. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Animal experiments were approved by the Animal Care Use and Review Committee of Center Research -Hospital Maisonneuve Rosemont (CR-HMR) (ethical approval no 2021-2516, 2023-3032 and 2024-3547) from University of Montreal. For mouse tumor experiments, all tumor sizes\/burdens were permitted by the CR-HMR of Montreal University. Maximal tumor burden permitted by the CR-HMR (1.5\u2009cm3) was not exceeded in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal ethics approval"}}],"article-number":"188"}}